Over the last decades, combined chemotherapies that inhibit different signalling pathways together have been demonstrated to be more effective to treat the non-small-cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) and the vascular endothelium growth factor (VEGF) are two key targets. Polymorphisms in EGFR and VEGF genes have been identified to be associated with therapy-response and cancer survival. In this study, we hypothesized that single-nucleotide polymorphisms (SNPs) of EGFR and VEGF genes are associated with NSCLC patients' survival in Chinese. Therefore, we screened and genotyped 54 potentially functional SNPs as well as tagging SNPs in these two genes using Illumina Golden Gate platform in 568 NSCLC patients. We found that subjects carrying EGFR rs3735061AA and rs6958497AG/GG genotypes survived significantly shorter time [median survival time (MST): 22.2 and 19.4 months, respectively] than those carrying rs3735061AG/GG (MST: 25.1 months) and rs6958497AA (MST: 25.9 months) (log-rank P 5 0.015 for rs3735061 and log-rank P 5 0.028 for rs6958497). However, subjects carrying EGFR rs759165AG/AA genotypes survived significantly longer (MST: 38.7 months) than those carrying rs759165GG genotype (MST: 24.7 months) (log-rank P 5 0.024). Multivariate Cox regression analyses showed that the genotypes of rs3735061AA and rs6958497AG/GG were associated with a significantly increased risk of death for NSCLC [hazard ratio (HR) 5 2.82, 95% confidence interval (CI) 5 1.66-4.78 for rs3735061AA and HR 5 1.69, 95% CI 5 1.26-2.28 for rs6958497AG/GG], whereas the rs759165AG/AA were associated with a 44% significantly decreased risk of death of NSCLC (HR 5 0.56, 95% CI 5 0.39-0.83). Stepwise COX regression analyses suggested that EGFR rs373506, rs759165 and rs6958497 may be independent candidate biomarkers to predict NSCLC survival in this population.
Introduction
Lung cancer is the leading cause of deaths from malignancy worldwide, due to its high incidence, malignant behaviour and lack of effective treatment (1) . In China, there were $500 000 lung cancer patients and 430 000 deaths in 2005, and the number of deaths will be .1 million by 2025 (2) (3) (4) . Despite the advances achieved in diagnosis and treatment in the last decades, the overall prognosis of lung cancer remains poor. The 5 year survival rate of non-small-cell lung cancer (NSCLC) is $15% in the USA but .9% in developing countries (1) .
Lung cancer is a highly heterogeneous disease. It has been reported that multiple mutations, a multitude of cellular components and patterns of gene expressions can affect treatment-response and prognosis of lung cancer (5, 6) . Over the last decades, a growing body of preclinical studies suggested that combined chemotherapies that inhibit different signalling pathways together had the potential to be more effective than monotherapy (7) . Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors have become two key targets of treatment of several cancers, including NSCLC (8) .
EGFR is a 170 kDa transmembrane glycoprotein with an intracellular tyrosine protein kinase domain that plays critical cellular signalling roles in diverse pathways (9) . EGFR activation leads to many biological processes, including cell cycle progression, cell invasion, metastasis, angiogenesis and cell differentiation, that are all closely related to tumour progression (10) . In transgenic mice, overexpression of EGFR initiates the formation of oligodendroglioma and breast cancer (11, 12) . In humans, EGFR is overexpressed in 50-81% of NSCLC and its overexpression has been demonstrated to correlate with poor prognosis of NSCLC (13, 14) .
Tumour growth requires an adequate blood supply (15) . VEGF is a predominant stimulator of angiogenesis and a validated therapeutic target for NSCLC (16) . VEGF is secreted by tumour cells in the majority of cancers and acts on endothelial cells of existing blood vessels to promote the formation of new blood vessels (17) . Increasing expression of VEGF is observed in $30 to 40% of NSCLC and is associated with poor survival of NSCLC (18) (19) (20) . Besides, microvessel count, which is correlated with VEGF expression, is an indication of angiogenic effect and an independent predictor of poor survival in patients with NSCLC (18) .
The EGFR and VEGF pathways are closely related. They share the common downstream signalling pathway and exert effects both directly and indirectly on tumour cells (8) . In addition, EGFR activation can induce the production of VEGF in human cancer cells, and conversely, blockade of EGFR can decrease the expression of VEGF in vivo (21, 22) . The inhibition of EGFR leads to downregulation of the phosphatidylinositol-3-kinase/Akt pathway that decreases the promoter activity of VEGF through decreasing Sp1 binding to the proximal core VEGF promoter and downregulating hypoxia-inducible factors-1a expression (23) . In turn, blockade of VEGF inhibits EGFR autocrine signalling and enhances the action of drugs targeting EGFR (24, 25) .
Considering the important roles of these two closely related genes in cell growth, differentiation and metastasis, we hypothesized that singlenucleotide polymorphisms (SNPs) in EGFR and VEGF genes may individually and jointly contribute to the prognosis of NSCLC. To test this hypothesis, we screened and genotyped 54 SNPs in EGFR and VEGF and evaluated the associations between these SNPs and NSCLC-specific survival in a cohort of 568 NSCLC patients in a Chinese population.
Subjects and methods

Study population
Our study was approved by the Institutional Review Board of Nanjing Medical University. A total of 1099 patients with histologically confirmed NSCLC were prospectively recruited into Nanjing Lung Cancer Study from the Cancer Hospital of Jiangsu Province and the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, since July 2003 to April 2008. All patients were face-to-face interviewed to collect demographic data (e.g. age and sex) and exposure information (e.g. smoking status). Each patient donated 5 ml venous blood after providing a written informed consent. Of 1099 patients, 828 patients (75.3%) had complete clinical information and responded in the first follow-up at the third month after enrollment (26, 27) . Patients who entered the case cohort were followed up every 3 months prospectively by personal Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; MST, median survival time; NSCLC, non-small-cell lung cancer; SNP, single-nucleotide polymorphism; VEGF, vascular endothelium growth factor. were genotyped by using the Illumina Golden Gate platform at Berkeley Biotech (Taizhou, China) and the information on assay conditions, primers and probes was available upon request. The quality control method for the Illumina highthroughput genotyping platform was described previously (28) . One blank well and three repeated samples were set for each 96-well assay plate to prevent contamination and to judge the clusters of genotype. At last, 45 SNPs (32 in EGFR and 13 in VEGF) were successfully genotyped with call rates ! 95% (average call rate: 99.7%) and also consistent with Hardy-Weinberg equilibrium (P . 0.05), whereas 4 SNPs (rs9642564, rs4947978 and rs13222549 in EGFR and rs833061 in VEGF) with low call rates (,95%) and 5 SNPs (rs759167, rs7780270, rs845560, rs2740761 and rs2740763 in EGFR) deviated from Hardy-Weinberg equilibrium (P 0.05) were removed from our further analysis.
Statistical analysis
Survival time was calculated from the date of NSCLC diagnosis to the date of death or last follow-up. The associations between survival time and demographic characteristics, clinical features and SNPs in EGFR and VEGF were estimated using the Kaplan-Meier method and the log-rank test. Mean survival time was present when the median survival time (MST) could not be calculated. Univariate and multivariate Cox proportional hazards regression models were fitted to estimate the crude hazard ratios (HRs), adjusted HRs and their 95% confidence intervals (CIs), with adjustment for age, sex, histology, stage, surgical operation and chemotherapy or radiotherapy status. The Cox stepwise regression analysis was also performed to determine predictive factors for NSCLC prognosis, with a significance level of 0.05 for entering and 0.051 for removing the respective explanatory variables. All the statistical analyses were carried out by Statistical Analysis System software (version 9.1.3; SAS Institute, Cary, NC). All statistical evaluations were made assuming a twosided test with the significant level of 0.05, if not specially stated otherwise.
Results
Patient characteristics and clinical features
The distribution of demographic characteristics and clinical factors of NSCLC patients was shown in Table I . The median age was 60 years old (range, 25-83 years) for the 568 patients retained in the study, and 76.4% was male. In the follow-up period (maximum follow-up time: 72 months), 311 patients were died of NSCLC and 3 died from other causes considered as censored data in the analyses. As expected, patients with advanced stage NSCLC had significantly shorter survival time (log-rank P , 0.001, Table I ). Surgical resection could significantly improve the prognosis of NSCLC (log-rank P , 0.001) but treatments with only chemotherapy or radiotherapy did not (logrank P 5 0.102). Univariate Cox regression analysis showed that the risk of death of NSCLC was significantly increased as the stage pro- Effects of EGFR and VEGF genotypes on NSCLC survival Log-rank test was used to assess the associations between EGFR and VEGF polymorphisms and NSCLC survival in different genetic models (Table II) . In the additive model, variant genotypes of two SNPs (rs3735061 and rs759165) in EGFR and two SNPs (rs3025039 and rs3025040) in VEGF were significantly associated with the survival of NSCLC (log-rank P 5 0.044, 0.024 for rs3735061 and rs759165 in EGFR; log-rank P 5 0.003, 0.004 for rs3025039 and rs3025040 in VEGF, respectively). In the dominant model, variant genotypes of EGFR rs6958497 were significantly associated with the survival of NSCLC (log-rank P 5 0.028). Furthermore, variant genotypes of EGFR rs3735061 and VEGF rs3025039, rs3025040 were also observed to be associated with NSCLC prognosis in the recessive genetic model (log-rank P 5 0.015 for rs3735061 in EGFR; log-rank P 5 0.004, 0.004 for rs3025039 and rs3025040 in VEGF, respectively). Multivariate Cox regression analyses revealed that significantly worse survival of NSCLC was associated with EGFR rs3735061 (AA versus GG/AG: HR 5 2.66, 95% CI 5 1.57-4.51) and EGFR rs6958497 (AG/GG versus AA: HR 5 1.43, 95% CI 5 1.07-1.89), whereas the significantly better survival of NSCLC was associated with EGFR rs759165 (AG/AA versus GG: HR 5 0.68, 95% CI 5 0.47-0.97). VEGF rs3025039 and rs3025040 were in high linkage disequilibrium (r 2 5 0.99) and there were no associations between these two SNPs and survival of NSCLC in the multivariate regression analyses when adjusted for age, gender, histology, stage, surgical operation and chemotherapy or radiotherapy status (AA versus AG/GG: HR 5 1.54, 95% CI 5 0.81-2.92 for Other carcinomas include large cell, undifferentiated and mixed-cell carcinomas.
EGFR (Table III) . Furthermore, we conducted Fisher's exact test to assess the associations between polymorphisms of the three independent predictors (rs3735061, rs759165 and rs6958497) and prognostic factors. Only one significant association between stage and rs759165 genotypes (Fisher's exact P 5 0.024) was found. It seems that the patients who carried rs759165GG genotype may present advanced stages (supplementary Table 1 is available at Carcinogenesis Online).
Stepwise (Table IV) . Furthermore, when age and sex were included in the final model, the rs3735061AA genotype contribute a 2.82-fold (95% CI 5 1.66-4.78) increased risk of death for NSCLC compared with the rs3735061AG/GG genotypes and rs6958497AG/ GG genotypes were also associated with worse survival (HR 5 1.69, 95% CI 5 1.26-2.28) compared with rs6958497AA genotype, whereas the rs759165AG/AA genotypes showed a significantly protective effect on NSCLC survival compared with the rs759165GG genotype (HR 5 0.57, 95% CI 5 0.39-0.83).
Combined effects and stratified analysis
We assessed the combined effects of the three independent predictors of rs3735061, rs759165 and rs6958497 on NSCLC survival. As shown in Table V , the results showed that the more unfavourable Table 2 is available at Carcinogenesis Online). However, there were no significant interactions between the combined genotypes and demographic characteristics and clinical factors on NSCLC survival (detailed data not shown). Kaplan-Meier survival curves for the combined genotypes were shown in Figure 1 .
Discussion
In this case cohort study with comprehensive assessment on SNPs in EGFR and VEGF, we investigated the effects of 54 potentially functional and tagging SNPs on NSCLC prognosis in a Chinese population. The results indicated that EGFR rs3735061, rs759165 and EGFR and VEGF polymorphisms and NSCLC prognosis rs6958794 may individually and jointly contribute to the survival of NSCLC in this population. The cell surface receptor family consists of four subfamilies. The most extensively studied family was EGFR. At the late 1990s, EGFR was discovered to play an important role in tumour biology and to be an attractive therapeutic target (29) . Increased EGFR-mediated signalling may drive a cell moving into a state of continuous, unregulated proliferation, thereby expanding the population of malignant cells and rapidly increasing tumour mass (7) . Several studies showed that overexpression of EGFR were associated with aggressiveness, poor response to cytotoxic agents and decreased overall survival in a variety of tumours, including NSCLC (13, 14, 30, 31) . Polymorphisms in EGFR gene was previously reported in relation to the changes of the level or activity of EGFR protein and the prognosis of many common cancers, such as NSCLC, breast cancer, oral cancer and gastrointestinal cancer (29, (32) (33) (34) . From the present study, we found that rs3735061, rs759165 and rs6958497, polymorphisms within EGFR intron 1, were independent predictors for NSCLC survival. The transcription of EGFR gene is regulated by two enhancer elements. The first one is located upstream near the transcription initiation site and the second one is in intron 1 (35, 36) . Therefore, the polymorphisms within EGFR intron 1 might play a role in influencing survival via regulating the transcription of EGFR. Preclinical studies in head and neck cancer cell lines demonstrated that polymorphisms in EGFR intron 1 were associated with different responses to EGFR tyrosine kinase inhibitors and thus resulted in different clinical outcomes (37) . Furthermore, the EGFR rs3735061, rs759165 and rs6958497 SNPs may contribute to NSCLC survival by themselves and also may be in high linkage disequilibrium with other truly functional ones to be identified further.
Activation of EGFR initiates signal transduction cascades that affect angiogenesis (38) . Angiogenesis, defined as the formation of new blood vessels from existing vasculature, is an important process regulating the growth and development of malignancies and also be critical in the invasion and metastasis of tumour cells (39) (40) (41) . VEGF, the key angiogenic promoter in physiological and also pathophysiological conditions, is a specific mitogen and survival factor for endothelial cells. The increasing vascularity of tumours is associated with worse prognosis, so the inhibition of VEGF can suppress tumour growth and angiogenesis (18, 42) . Several studies have reported that polymorphisms in the VEGF gene can affect the prognosis of diverse cancers, such as breast cancer, gastric cancer, ovarian cancer and NSCLC (43) (44) (45) (46) . Heist et al. (45) found that there was a trend towards improved survival among patients carrying the variant A allele of the rs3025039 (þ936T allele in their study) in early-stage NSCLC, but without statistical significant. However, the risk of death might be differed by different ethnic background and different disease stage. Masago et al. (47) reported that rs3025039 was not associated with advanced NSCLC survival. In our current study, we didnot find any significant association between VEGF polymorphisms and NSCLC survival in patients including all stages. Although the rs3025039AA genotype was associated with the significantly worse survival of NSCLC in recessive model without adjusted for age, gender, histology, surgical operation and chemotherapy or radiotherapy, the results may be obtained by chance because of the relatively small number of subjects carrying this genotype.
There were several limitations in our study. Firstly, it should be noted that drugs target EGFR and VEGF were not widely used in our patient cohort. For only 21 patients took the targeted therapy, we could not further analyze the relationships between these SNPs and the specific drug-response, but the trend of the analysis did not change when excluding these subjects. Secondly, restricted by the genotyping platform, some genetic variants that may be important in NSCLC prognosis were not included (e.g. insert/deletion or tandem repeat polymorphisms) or failed to be genotyped (e.g. SNPs with design score , 0.50). Thirdly, after Bonferroni corrections, none of the associations were still significant with the significance level of 0.001. False-positive report probability analysis revealed that all positive findings remained significant assigning prior probability .0.1, but the associations may be less convincing setting the prior probability of 0.01, when considering 0.5 as the false-positive report probability level criterion based on the potential functional significance of the selected SNPs (48) . Therefore, large well-designed studies with diverse populations and functional characteristics are warranted to confirm our findings.
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